Guggenheim began coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research note released on Thursday morning, 24/7 WallStreet reports. The brokerage issued a buy rating and a $25.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on the company. Citigroup reissued a buy rating and issued a $26.00 target price (up from $20.00) on shares of Fate Therapeutics in a research report on Friday, May 24th. BidaskClub raised Fate Therapeutics from a hold rating to a buy rating in a research report on Friday, May 17th. Zacks Investment Research downgraded Fate Therapeutics from a hold rating to a sell rating in a research report on Friday, May 10th. Svb Leerink assumed coverage on Fate Therapeutics in a research report on Thursday, March 28th. They issued an outperform rating and a $20.00 target price on the stock. Finally, Leerink Swann assumed coverage on Fate Therapeutics in a research report on Thursday, March 28th. They issued an outperform rating and a $20.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $20.89.

Shares of FATE stock opened at $19.28 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.40 and a quick ratio of 6.40. Fate Therapeutics has a 12-month low of $8.64 and a 12-month high of $20.65.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Fate Therapeutics had a negative return on equity of 54.30% and a negative net margin of 1,138.12%. The business had revenue of $2.63 million for the quarter, compared to analyst estimates of $2.01 million. During the same period in the previous year, the company posted ($0.27) earnings per share. The business’s revenue for the quarter was up 156.3% on a year-over-year basis. As a group, research analysts expect that Fate Therapeutics will post -1.25 earnings per share for the current fiscal year.

In related news, insider J Scott Wolchko sold 14,335 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $19.37, for a total value of $277,668.95. Following the transaction, the insider now directly owns 389,216 shares of the company’s stock, valued at approximately $7,539,113.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Daniel D. Shoemaker sold 12,500 shares of the company’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $16.94, for a total value of $211,750.00. Following the completion of the transaction, the insider now directly owns 148,091 shares in the company, valued at $2,508,661.54. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,376 shares of company stock worth $979,727. 23.19% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Ladenburg Thalmann Financial Services Inc. purchased a new stake in Fate Therapeutics in the first quarter valued at $42,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Fate Therapeutics by 61.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,865 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,464 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in Fate Therapeutics by 248.5% in the first quarter. Meeder Asset Management Inc. now owns 2,826 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 2,015 shares during the last quarter. Creative Planning purchased a new stake in Fate Therapeutics in the fourth quarter valued at $141,000. Finally, Legal & General Group Plc boosted its holdings in Fate Therapeutics by 48.6% in the fourth quarter. Legal & General Group Plc now owns 11,376 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 3,719 shares during the last quarter. 93.28% of the stock is currently owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

See Also: Call Option

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.